不同剂量沙美特罗替卡松辅助治疗支气管哮喘临床评价

Clinical Evaluation of Different Doses of Salmeterol and Fluticasone in Adjuvant Treatment of Bronchial Asthma

目的观察不同剂量沙美特罗替卡松辅助治疗支气管哮喘的临床疗效及安全性。方法选择同期住院治疗的支气管哮喘患者92例,随机均分为低剂量组与高剂量组,两组在相同基础治疗基础上,低剂量组给予沙美特罗替卡松吸入剂50μg/250μg,高剂量组给予50μg/500μg。结果高剂量组患者各临床症状缓解时间均短于低剂量组患者(P<0.05);治疗10 d后高剂量组患者肺功能指标与哮喘症状评分均优于低剂量组患者(P<0.05),治疗30 d与90 d后,两组患者肺功能指标与哮喘症状评分差异无统计学意义(P>0.05);两组患者治疗期间均无严重不良反应。结论支气管哮喘发作期应首选沙美特罗替卡松高剂量治疗,利于患者临床症状的控制;稳定期应首选低剂量治疗,哮喘症状控制满意且安全可靠。

Objective To observe the clinical efficacy and safety of different doses of salmeterol and fluticasone in adjuvant treatment of bronchial asthma. Methods Totally 92 patients with bronchial asthma admitted to our hospital in the same period were selected and randomly divided into the low dose group and the high dose group. On the basis of same basic treatment, the low dose group and the high dose group were treated with 50 μg/250 μg,50 μg/500 μg Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhala-tion, respectively. Results The remission time of the clinical symptoms in the high dose group was shorter than that in the low dose group （ P 0. 05 ） . No serious adverse reactions occurred in the two groups during the treatment. Conclusion In the attack stage of bronchial asthma, high dose of salmeterol and fluticasone should be the first choice for treatment, which can control the clinical symptoms of the patients. In the stable stage of bronchial asthma, low dose of salmeterol and fluticasone should be the first choice for treatment, which can well control the symptoms of asthma, and it is safe and reliable.